251 related articles for article (PubMed ID: 11336479)
1. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
Jerome KR; Domenech N; Finn OJ
J Immunol; 1993 Aug; 151(3):1654-62. PubMed ID: 8393050
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
[TBL] [Abstract][Full Text] [Related]
5. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
[TBL] [Abstract][Full Text] [Related]
7. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
9. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
Barratt-Boyes SM; Vlad A; Finn OJ
Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
[TBL] [Abstract][Full Text] [Related]
10. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
[TBL] [Abstract][Full Text] [Related]
11. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.
Takahashi T; Makiguchi Y; Hinoda Y; Kakiuchi H; Nakagawa N; Imai K; Yachi A
J Immunol; 1994 Sep; 153(5):2102-9. PubMed ID: 8051415
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel bi-specific monoclonal antibody approach for tumour targeting.
Koumarianou AA; Hudson M; Williams R; Epenetos AA; Stamp GW
Br J Cancer; 1999 Oct; 81(3):431-9. PubMed ID: 10507767
[TBL] [Abstract][Full Text] [Related]
13. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study.
Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
Immunol Invest; 2009; 38(8):820-38. PubMed ID: 19860591
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
15. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.
Mukherjee P; Ginardi AR; Tinder TL; Sterner CJ; Gendler SJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):848s-855s. PubMed ID: 11300482
[TBL] [Abstract][Full Text] [Related]
16. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.
van de Wiel-van Kemenade E; Ligtenberg MJ; de Boer AJ; Buijs F; Vos HL; Melief CJ; Hilkens J; Figdor CG
J Immunol; 1993 Jul; 151(2):767-76. PubMed ID: 7687622
[TBL] [Abstract][Full Text] [Related]
17. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
[TBL] [Abstract][Full Text] [Related]
18. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
20. MUC1 and breast cancer.
Apostolopoulos V; Pietersz GA; McKenzie IF
Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]